RxDoctor Payments Data

Matthew Bell, MD

Family Medicine · Garland, TXNPI 1558921981

Payments from drug & device makers

$1,394in general payments, 2019–2025

Across 68 payments — averaging $20.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$215
  • Astellas Pharma US Inc$203
  • Mallinckrodt Hospital Products Inc.$146
  • Lilly USA, LLC$121
  • AstraZeneca$90
  • Dexcom, Inc.$90
  • plus $530 from 15 others

What the payments were for

  • Food & beverage$1,29993%
  • Education$957%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,394 in reported general payments places this provider in the 65th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$77,398
Medicare patients
196
Services billed
1,516

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide30$35,800
JanuviaSitagliptin Phosphate16$20,321
EliquisApixaban12$12,923
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,516
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$5,912
Fluticasone-SalmeterolFluticasone Propion/Salmeterol29$3,570
Gabapentin107$2,033
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$1,878
Tamsulosin Hcl92$1,786
Atorvastatin Calcium201$1,632
Duloxetine Hcl42$1,303
Rosuvastatin Calcium84$1,265
Levothyroxine Sodium112$979
Albuterol Sulfate HfaAlbuterol Sulfate37$973
Fluticasone Propionate57$962

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta$14$14,42826 claims
PfizerEliquis$215$12,92312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Garland

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →